echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Annual Inventory 2022 Multiple Myeloma Progress Summary (Part I) – Voice of Experts

    Annual Inventory 2022 Multiple Myeloma Progress Summary (Part I) – Voice of Experts

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Multiple myeloma (MM) is a malignant plasma cell disease, accounting for about 10% of hematologic malignancies, second only to non-Hodgkin lymphoma, and more likely to occur in middle-aged and elderly people
    In recent years, with the continuous advent of new drugs and the innovation of treatment methods, MM treatment has been gradually optimized and improved
    In 2022, the Department of Hematology cooperated with a number of big coffee to discuss MM-related progress, and this issue of "Annual Inventory" selects and summarizes the interviews/reviews of MM experts in 2022, click
    on the article to read the original article

    Bispecific antibodies1

    2022 ASH Lessons from the Army | New therapies for myeloma: Talquetamab has an ORR of more than 70% for the treatment of multiple refractory myeloma


    2022 ASH | Professor Xia Zhongjun: With the help of single and double antibodies, RRMM can be expected in the future


    2022 EHA | Professor Niu Ting: The prospect of bispecific antibody therapy for RRMM is promising, and the combination with Dara creates more possibilities

    Monoclonal antibodies1

    2022ASH Voices | Professor Fu Weijun: Daratumumab contributes to the treatment of patients with multiple myeloma with renal insufficiency!


    2022 ASH | Professor Jin Fengyan: The combination of four anti-CD38 monoclonal antibodies may solve the high-risk NDMM dilemma


    2022 EHA Focused Monoclonal Antibody | Professor Fu Chengcheng: Daratumab treatment of newly diagnosed multiple myeloma data express

    XPO-1 inhibitor

    2022 EHA Professor Fu Weijun: Seliniso combined with dexamethasone brings effective remission to patients with R/R MM after CAR-T treatment


    Case sharing | Professor Zhang Xi commented: XPO1 inhibitor celinisol brings a new choice for patients with R/R MM with extramedullary lesions


    Case Sharing | Professor Wang Luqun commented: Targeted therapy has shown its strength, and the combination of celiniso has been used on the front line to bring relief to MM patients involved in CNS!


    Expert consensusProfessor Wu Depei, Professor Hu Yu and Professor Li Juan: The expert consensus on the clinical application of celiniso in multiple myeloma (2022) was officially released, helping to standardize the use of celiniso!

    CAR-T cell therapy1

    New options for RRMM patients, BCMA CAR-T clinical case sharing

    Autologous NK cell therapy

    EHA Reviews | Professor Huang Wenrong: Autologous NK cell therapy is safe and feasible as a first-line consolidation therapy after ASCT in patients with multiple myeloma, and it is worth exploring

    Proteasome inhibitors

    EHA Interview | Professor Niu Ting: Novel proteasome inhibitors may change the treatment pattern of patients with relapsed/refractory multiple myeloma


    2022 ASH Express | Professor Chen Wenming: The new generation of proteasome inhibitor carfilzomib has good efficacy and safe tolerance in the treatment of RRMM

    Hematopoietic stem cell transplantation1

    Professor Huang Wenrong: Research progress of autologous hematopoietic stem cell transplantation in multiple myeloma with renal insufficiency2022 Chinese Hematology Conference


    Professor Wang Zhiguo: Autologous hematopoietic stem cell transplantation treatment for elderly multiple myeloma| The 7th International Summit Forum on Anti-leukemia and Lymphoma

    Prognosis judgment and efficacy assessment1

    Professor Wang Yafei: Clinical value of 1q abnormalities in MM


    Reviews | Professor Liu Aijun: Clinical significance of negative loss of minimal residual disease for multiple myeloma


    2022CSH |Professor Sun Chunyan: Application and research progress of circulating tumor plasma cell detection in the clinical diagnosis and treatment of multiple myeloma

    MM optimizes the path
    to treatment1

    Professor Hu Yu: Focus on the quality of life of MM and go to the road of PRO-oriented treatment optimization


    2022CSH | Professor Niu Ting: Based on the present and looking to the future, the development of multiple myeloma treatment in China


    2022 SHS | Professor Fu Chengcheng: Jointly build a "blood think tank" to explore a new direction for MM diagnosis and treatment optimization


    Professor Fang Baijun: From the status quo to progress, look at the breakthrough of immunotherapy in R/R MM


    Professor Zhong Yuping | The era of immunotherapy: how to successfully break through the treatment of high-risk multiple myeloma?


    2022 EMN Annual Meeting | Immunotherapy "blooms" to help MM precision treatment

    Finishing: Quinta Typesetting: Quinta Execution: Cherry

    Disclaimer: This platform is designed to deliver more medical information
    to healthcare professionals.
    The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
    If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
    The content published by this platform does not mean that it agrees with its description and views
    If copyright issues are involved, please contact us and we will deal with
    it as soon as possible.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.